MedTrace Logo

Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.

NCT00502034 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2013-07-10

No results posted yet for this study

Summary

The aim of this study is to compare the efficacy (in terms of event-free survival and overall survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see program in patient with radically operated renal cell carcinoma.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Interferon Alfa-2a

Interferon Alfa-2a in combination with Interleukin

DRUG

Interleukin-2

Interferon Alfa-2a in combination with Interleukin

Sponsors & Collaborators

  • Gruppo Oncologico Italiano di Ricerca Clinica

    lead OTHER

Principal Investigators

  • Rodolfo Passalacqua, Medicine · Gruppo Oncologico Italiano di Ricerca Clinica

  • Carlo Buzio, Medicine · Parma University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-07-31
Primary Completion
2007-04-30
Completion
2012-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502034 on ClinicalTrials.gov